Esomeprazole Affects QOL

OCTOBER 01, 2005

Gastroesophageal reflux disease (GERD) can significantly impair health-related quality of life (QOL). In their study, F. Pace, MD, and colleagues assessed the effects of esomeprazole (a proton pump inhibitor) therapy on QOL in patients with GERD (n = 6017). Upon enrollment, patients received esomeprazole (40 mg/day) acutely for 4 weeks. If this treatment was successful, they were randomly assigned to 2 maintenance esomeprazole treatment strategies: continuous (20 mg/day) or on demand (for 6 months). QOL was measured at baseline by the generic Short-Form 36 Questionnaire and by a disease-specific instrument, QOL in Reflux and Dyspepsia (QOLRAD).

After the acute treatment phase, all QOLRAD dimensions showed statistically significant (P < .0001) and clinically meaningful improvement. There was a statistically significant but small difference in QOLRAD scores at the end of the maintenance phase in favor of the continuous versus the on-demand regimen. Improved QOL was maintained during the 6-month followup, with patients favoring the continuous- treatment strategy, according to a study in Alimentary Pharmacology & Therapeutics (September 2005).



SHARE THIS SHARE THIS
0

Conference Coverage from ASHP Summer 2017 

Four years after they first launched the Summer Meetings in Minneapolis, Minn., the ASHP 2017 Summer Meetings and Exhibition was in Minneapolis once again.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.